TY  - JOUR
AU  - Rowland, Andrew
AU  - Sorich, Michael J.
PY  - 2017
TI  - Preface to Precision Dosing of Targeted Anti-Cancer Drugs
JF  - Translational Cancer Research; Vol 6, Supplement 10 (December 14, 2017): Translational Cancer Research (Focused Issue: Precision Dosing of Targeted Anticancer Drugs)
Y2  - 2017
KW  - 
N2  - Small molecule protein kinase inhibitors (KIs) and anti-neoplastic monoclonal antibodies (mAbs) are rapidly expanding classes of non-cytotoxic or ‘targeted’ antineoplastic drugs that are effective at treating numerous malignancies, including previously difficult to treat forms of cancers. However, variability in disposition causes inter-individual variability in drug exposure that is inadequately addressed by the standard fixed-dose schedule of administration (1). Accordingly, precision dosing has great potential to maximise therapeutic response, minimise adverse drug reactions (ADRs), and improve cost-effectiveness of these expensive drugs.
UR  - https://tcr.amegroups.org/article/view/17572